Trends in Nanopharmaceutical Patents
by
Adelaide Antunes 1,2,*,†, Iolanda Fierro 1,†, Rafaela Guerrante 1, Flavia Mendes 2 and Maria Simone de M. Alencar 3
Adelaide Antunes 1,2,*,†, Iolanda Fierro 1,†, Rafaela Guerrante 1, Flavia Mendes 2 and Maria Simone de M. Alencar 3
1
National Institute of Industrial Property (Brazil), Mayrink Veiga, n° 9 Centro, Rio de Janeiro, Brazil
2
Federal University of Rio de Janeiro, Postgraduate Program on Technology of Chemical & Biochemical Processes, Av. Horácio Macedo, 2030, Centro de Tecnologia, Bloco I sala I-222, Cidade universitária, Rio de Janeiro, Brazil
3
Oswaldo Cruz Foundation, Institute of Scientific and Technological Communication and Information in Health, Av. Brasil, number 4.365 - Pavilhão Haity Moussatché - Manguinhos, Rio de Janeiro 21.045-360, Brazil
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Int. J. Mol. Sci. 2013, 14(4), 7016-7031; https://doi.org/10.3390/ijms14047016
Received: 28 December 2012 / Revised: 14 March 2013 / Accepted: 15 March 2013 / Published: 27 March 2013
(This article belongs to the Special Issue Bioactive Nanoparticles 2012)
Investment in nanotechnology is now a given constant by governments, research centers and companies in both more developed countries and emerging markets. Due to their characteristics, such as high stability, ability to enable antigen identification on specific cells in the human body and controlling the release of drugs and, therefore, improving therapies, nanoparticles have been the subject of research and patent applications in the pharmaceutical field. According to the Organization for Economic Co-operation and Development (OCDE), patent data can be used as a source of information in order to measure science and technology activities. Thereby, this paper presents an analysis based on patent documents related to nanotechnology in the pharmaceutical sector. As a result, the analysis of patents demonstrate primarily that nanobiotechnology attracts high levels of R&D investments, including nanoparticle-based chemotherapeutic agents/drugs, monoclonal antibody nanoparticle complexes and their role in drug delivery or contrast agents with non-toxic effects.
View Full-Text
Keywords:
health; patents; nanotechnology; pharmaceutical
▼
Show Figures
Graphical abstract
This is an open access article distributed under the Creative Commons Attribution License
MDPI and ACS Style
Antunes, A.; Fierro, I.; Guerrante, R.; Mendes, F.; Alencar, M.S.M. Trends in Nanopharmaceutical Patents. Int. J. Mol. Sci. 2013, 14, 7016-7031.
Show more citation formats